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Background
Daptomycin is a lipopeptide with bactericidal activity that acts on the cell membrane 
of enterococci and is often used off-label to treat patients infected with vancomycin-
resistant enterococci. However, the emergence of resistance to daptomycin during 
therapy threatens its usefulness.
Methods
We performed whole-genome sequencing and characterization of the cell envelope 
of a clinical pair of vancomycin-resistant Enterococcus faecalis isolates from the blood 
of a patient with fatal bacteremia; one isolate (S613) was from blood drawn before 
treatment and the other isolate (R712) was from blood drawn after treatment with 
daptomycin. The minimal inhibitory concentrations (MICs) of these two isolates were 
1 and 12 μg per milliliter, respectively. Gene replacements were made to exchange 
the alleles found in isolate S613 with those in isolate R712.
Results
Isolate R712 had in-frame deletions in three genes. Two genes encoded putative en-
zymes involved in phospholipid metabolism, GdpD (which denotes glycerophospho-
ryl diester phosphodiesterase) and Cls (which denotes cardiolipin synthetase), and 
one gene encoded a putative membrane protein, LiaF (which denotes lipid II cycle-
interfering antibiotics protein but whose exact function is not known). LiaF is 
predicted to be a member of a three-component regulatory system (LiaFSR) involved 
in the stress-sensing response of the cell envelope to antibiotics. Replacement of the 
liaF allele of isolate S613 with the liaF allele from isolate R712 quadrupled the MIC of 
daptomycin, whereas replacement of the gdpD allele had no effect on MIC. Replace-
ment of both the liaF and gdpD alleles of isolate S613 with the liaF and gdpD alleles 
of isolate R712 raised the daptomycin MIC for isolate S613 to 12 μg per milliliter. 
As compared with isolate S613, isolate R712 — the daptomycin-resistant isolate 
— had changes in the structure of the cell envelope and alterations in membrane 
permeability and membrane potential.
Conclusions
Mutations in genes encoding LiaF and a GdpD-family protein were necessary and 
sufficient for the development of resistance to daptomycin during the treatment of 
vancomycin-resistant enterococci. (Funded by the National Institute of Allergy and 
Infectious Diseases and the National Institutes of Health.)
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The treatment of enterococcal in-fections has become an enormous challenge for clinicians because these organisms fre-
quently exhibit resistance to the standard drugs 
of choice — namely, ampicillin, vancomycin, and 
aminoglycosides (with high-level resistance to ami-
noglycosides). In addition, there has been a strik-
ing increase in the frequency of isolation and the 
spread of vancomycin-resistant enterococci in hos-
pitals around the world, which has resulted in sig-
nificant increases in mortality, length of hospital 
stay, and hospitalization costs.1
Enterococcus faecium is one of the so-called 
ESKAPE pathogens (E. faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudo-
monas aeruginosa, and enterobacter species) flagged 
by the Infectious Diseases Society of America as 
problem pathogens requiring new therapies.2 The 
Food and Drug Administration (FDA) has approved 
only two compounds for the treatment of vanco-
mycin-resistant enterococci infections: linezolid 
and quinupristin–dalfopristin. Both have impor-
tant limitations when used for the treatment of 
severe vancomycin-resistant infection. Their use 
often results in clinical failure or recurrence of 
infection; they have an adverse toxicity profile, 
a limited spectrum of activity, and a bacterio-
static effect against vancomycin-resistant entero-
cocci, and they are associated with increasing 
reports of resistance.
Daptomycin is a lipopeptide antibiotic with in 
vitro bactericidal activity against enterococci. Even 
though the FDA has not approved daptomycin for 
the treatment of infection with vancomycin-resis-
tant enterococci, clinicians often use it off-label 
in patients with severe enterococcal infections be-
cause of the lack of other treatment options with 
established reliability.3 However, a major draw-
back of the use of daptomycin for the treatment of 
infection with vancomycin-resistant enterococci is 
the development of resistance during therapy.4-6 
Although little is known about the mechanism of 
in vivo resistance, a critical step in the action of 
daptomycin is its interaction with the bacterial 
cell membrane in a calcium-dependent manner. 
In this study, comparative genomic sequencing and 
genetic manipulations of a clinical pair of dapto-
mycin-susceptible and daptomycin-resistant E. fae-
calis strains, which were recovered from the blood-
stream of a patient with fatal bacteremia, identified 
mutations in two genes not previously associated 
with antibiotic resistance in enterococci.
Me thods
bacterial isolates
The vancomycin-resistant clinical strain pair of 
daptomycin-susceptible and daptomycin-resistant 
E. faecalis has been described previously,4 as has a 
similar strain pair of E. faecium5 (for details, see 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org). We also stud-
ied, with the use of pulsed-field gel electrophore-
sis, six unrelated clinical isolates of daptomycin-
resistant enterococci (one E. faecalis isolate and five 
E. faecium isolates) recovered from different clini-
cal sources in the United States. A daptomycin-
resistant derivative of E. faecalis S613 was obtained 
after passing the bacterium through increasing 
subinhibitory concentrations of daptomycin twice 
daily for 17 days, starting with a concentration of 
0.5 μg per milliliter. (See the Supplementary Ap-
pendix for the selection protocol.)
Genomic Sequencing and analysis
Paired-end sequence reads of the E. faecalis strain 
pair (S613 and R712) were generated with the Il-
lumina Genome Analyzer IIx at the Washington 
University Genome Institute, producing 100 base-
paired end reads that were assembled with the 
use of Velvet software.7 Genomic analysis and com-
parisons were performed by applying standard 
methods (see the Supplementary Appendix for de-
tails). All synonymous and nonsynonymous mu-
tations were confirmed by means of polymerase-
chain-reaction (PCR) sequencing of both strands 
in accordance with the Sanger dideoxy-termina-
tor method of sequencing, with target genes re-
sequenced in their entirety. The homologues of 
the genes encoding the LiaFSR regulatory system 
(liaF, liaS, and liaR [lia denotes lipid II cycle-interfer-
ing antibiotics protein]),8 the glycerophosphoryl-
diester-phosphodiesterase (gdpD)–family protein, 
and cardiolipin synthetase (cls) were sequenced 
from all isolates and derivatives of S613.
Allelic Replacements
To establish a direct link between the presence of 
specific gene mutations and the development of 
the daptomycin-resistant phenotype, we replaced 
the native genes encoding the LiaF and GdpD 
proteins of the E. faecalis S613 isolate with those 
of the E. faecalis R712 isolate. The replacements 
were performed independently for each gene and 
then in combination, with the use of the p-chlo-
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rophenylalanine sensitivity counterselection sys-
tem, as described previously,9,10 except for the fact 
that plasmid pHOU3 was constructed and used 
(Fig. S1 in the Supplementary Appendix). The mu-
tants were characterized with the use of pulsed-
field gel electrophoresis, and the open reading 
frames of the three genes (liaF, cls, and gdpD) were 
sequenced. To detect small differences in the sus-
ceptibility to daptomycin, minimal inhibitory con-
centrations (MICs) were determined with the use 
of Etest (AB Biodisk).11
Ultrastructural Characteristics of the Cell 
Envelope
Transmission electron microscopy was used to as-
sess the ultrastructural characteristics of E. faeca-
lis strain pair S613 and R712 in accordance with 
standard methods.12 The number of cell-division 
events (cells with a septum) in 100 cells chosen 
randomly in two blinded experiments was also de-
termined with the use of transmission electron 
microscopy. The thickness of the cell walls was 
measured from the outer border of the cell mem-
brane to the outer edge of the cell wall (on the basis 
of 100 observations of each isolate with a mini-
mum of 50 cells, in cells from different fields, at 
a magnification of 190,000). The mean (±SD) cell-
wall thickness was determined for each strain, and 
mean differences were compared with the use of 
Student’s t-test.
Cell-surface charge, daptomycin-mediated cell-
membrane permeability, and the effect of dapto-
mycin on cell-membrane potential were measured 
with the use of a modified cytochrome c assay,13 
a highly sensitive bacterial viability kit (LIVE/DEAD 
BacLight, Invitrogen),14 and the cell-membrane 
potential-sensitive 3,3-dipentyoxacarbocyanine as-
say,15 respectively (see the Supplementary Appen-
dix for details).
R esult s
Mutations Conferring Daptomycin Resistance
A total of 3082 open reading frames were found 
in isolate S613 (2,727,367 base pairs were matched 
in both genomes), and comparative analysis and 
resequencing of genes of the clinical strain pair 
revealed changes in four predicted proteins in the 
daptomycin-resistant isolate, R712, as compared 
with the daptomycin-susceptible isolate, S613. 
Three of the four mutations consisted of in-frame 
deletions in a stretch encoding a repeated amino 
acid (Table 1). The proteins encoded included two 
enzymes (GdpD and Cls) predicted to be involved 
in phospholipid metabolism and likely to partici-
pate in cell-membrane homeostasis and a puta-
tive transmembrane protein that is a homologue 
of LiaF (48% similarity) from Bacillus subtilis8 (Ta-
ble 1). The regions of these predicted proteins 
are highly conserved among all E. faecalis isolates 
whose genomes have been sequenced, and these 
deletions are unique to the daptomycin-resistant 
isolate as compared with all E. faecalis homologues 
analyzed (www.ncbi.nlm.nih.gov//genomes/geblast 
.cgi?gi=7128#SearchSet). The fourth mutated 
gene encodes a putative LacI (lactose-operon-
repressor)-family transcriptional repressor that 
is probably involved in carbohydrate metabolism. 
However, the substitution (Gly→Val) in position 2 
is also present in other enterococcal homologues 
of the putative protein. It is of interest that none 
of the enterococcal homologues of staphylococ-
cal genes associated with daptomycin resistance 
in previous studies (mprF, yycG, yycH, dltABCD, rpoB, 
rpoC, vraSR, and graSR)20-24 exhibited any change 
when their gene sequences were compared with 
those of the vancomycin-resistant E. faecalis clinical 
strain pair.
To confirm the association of the genetic 
changes (Table 1) with the development of dap-
tomycin-resistance, we initially exposed the dap-
tomycin-susceptible E. faecalis S613 isolate to in-
creasing concentrations of daptomycin in vitro. 
A daptomycin-resistant derivative was readily ob-
tained after 17 days of exposure, with a daptomy-
cin MIC similar to that of R712 (isolate S613R) 
(Table 2). On pulsed-field gel electrophoresis, the 
S613R isolate had a pattern that was identical to 
that of isolate S613, and we identified the same 
mutations found in the genes encoding the LiaF 
protein and the GdpD enzyme (but not in cls), sug-
gesting that gdpD and liaF play a predominant role 
in the development of resistance to daptomycin in 
this in vitro–selected mutant.
To establish a direct link between the muta-
tions in these two genes and the development of 
resistance to daptomycin, we replaced the liaF and 
gdpD alleles of the S613 isolate with those derived 
from the R712 isolate, both individually and in 
combination (with liaF replaced first, followed by 
gdpD). The correct allelic replacements were con-
firmed by sequencing the corresponding entire 
open reading frames in all constructs (including 
the cls gene that was not manipulated and re-
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mained unchanged in all constructs). Table 2 
shows that the introduction of the liaF allele of 
the R712 isolate quadrupled the daptomycin MIC 
of the S613 isolate but not to the level of the R712 
isolate; replacement of the gdpD allele alone had 
no effect on the susceptibility of isolate S613 to 
daptomycin. However, when the gdpD allelic re-
placement was introduced into the S613 deriva-
tive harboring the deletion in liaF, the daptomy-
cin MIC was increased to 12 μg per milliliter — a 
concentration that was above the clinical break-
point and identical to that for isolate R712, con-
firming our in vitro observation that mutations 
in these two genes are necessary and sufficient to 
confer clinical resistance to daptomycin in E. fae-
calis isolate S613.
Ultrastructural Changes and Resistance
Transmission electron microscopy revealed im-
portant differences in the cell morphology of the 
two isolates; R712 cells tended to clump and 
formed aggregates with longer chains, as com-
pared with S613 cells. At higher magnifications, 
the presence of multiple septal structures before 
complete cell separation was evident in R712 
(Fig. 1). In addition, the R712 cell envelopes ap-
peared to be markedly altered as compared with 
those of the S613 isolate (Fig. 1). The number of 
cells with a septum was consistently higher in the 
R712 isolate than in the S613 isolate (P<0.001). The 
cell-wall thickness of R712 was also greater than 
that of S613 (average thickness, 18.12±2.23 nm 
vs. 10.43±1.34 nm; P<0.001). Collectively, our re-
sults suggest that the development of daptomycin 
resistance in vivo in E. faecalis is associated with 
profound ultrastructural changes in the cell en-
velope, septal apparatus, and cell wall. The devel-
opment of daptomycin resistance in R712 was also 
associated with a cell surface with a greater pos-
itive charge, striking reductions in daptomycin-
induced permeabilization of the cell membrane, 
and alterations in the ability of daptomycin to 
depolarize the membrane of the target cell, as 
compared with isolate S613 (Fig. S2 in the Sup-
plementary Appendix).
Mutations Identified in Other Enterococci
We sought to determine whether the genetic 
changes identified in the daptomycin-resistant 
strain of E. faecalis (Table 1) could also be found 
in other clinical isolates of daptomycin-resistant 
enterococci, particularly E. faecium, since infection 
with this species is much more difficult to treat 
than infection with E. faecalis. Indeed, in a clinical 
strain pair of E. faecium recovered from a patient 
before and after daptomycin therapy, we found an 
Arg218→Gln substitution in the Cls enzyme but 
not in the LiaFSR or GdpD proteins (Table 3). The 
Arg218→Gln substitution in Cls was also found in 
an unrelated daptomycin-resistant clinical isolate 
Table 1. Genetic Changes Identified in the Vancomycin-Resistant Enterococcus faecalis Isolate That Was Resistant to Daptomycin (Strain R712) 
as Compared with the Daptomycin-Susceptible Isolate (Strain S613).*
Predicted  
Gene Product†
Nucleotide Change  
in Strain R712
Predicted Amino Acid  
Change in Strain R712 Comments
LiaF Deletion of ATT Deletion of Ile at position  
177 in a stretch of four  
Ile residues
Part of a conserved gram-positive, three-component regulatory sys-
tem that orchestrates the cell-envelope response to antimicrobial 
peptides and antibiotics that target the cell membrane16-19; the 
Bacillus subtillis LiaF negatively interferes with histidine kinase 
(LiaS) autophosphorylation through direct interactions, thereby 
suppressing activation of the cognate response regulator (LiaR)8
GdpD Deletion of ATT Deletion of Ile at position  
170 in a stretch of four  
Ile residues
A transmembrane protein predicted to be involved in phospholipid 
metabolism; participates in glycerol metabolism in other organ-
isms through hydrolysis of several glycerophosphodiesters; the 
mutation occurs within a predicted transmembrane domain
Cls‡ Deletion of AAA Deletion of Lys at position  
61 in a stretch of three  
Lys residues
A transmembrane protein predicted to be involved in phospholipid 
metabolism; the putative enzyme contains two conserved phos-
pholipase D domains; the mutation is located nine amino acids 
away from the C-terminal of the second predicted transmembrane 
domain outside the phospholipase D domains
* Cls denotes cardiolipin synthetase, GdpD glycerophosphoryl diester phosphodiesterase, and LiaF lipid II cycle-interfering-antibiotics protein.8
† The genome accession numbers, locus tags, and gene homologues in E. faecalis V583 are specified in the Supplementary Appendix.
‡ In some E. faecalis genomes, the gene has been annotated as coding for a phospholipase D–transphosphatidylase enzyme.
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of E. faecium (isolate R501) (Table 3), suggesting 
that this switch in amino acids (within the phos-
pholipase D domain of the enzyme) may play an 
important role in the development of daptomycin 
resistance in E. faecium. Furthermore, we invariably 
found changes in cls, liaF, liaS, or liaR in other 
daptomycin-resistant clinical isolates of enterococ-
ci (Table 3).
Discussion
The off-label use of daptomycin occurs often in 
the treatment of severe enterococcal infections, 
including infections with vancomycin-resistant en-
terococci or those species exhibiting high-level re-
sistance to aminoglycosides. However, a major 
drawback for the successful use of this antibiotic 
is the emergence of resistance during therapy. In 
addition, in vitro, enterococci are less susceptible 
to daptomycin than S. aureus, with a clinical thresh-
old for sensitivity that is four times as high (≤4 μg 
per milliliter, vs. ≤1 μg per milliliter for S. aureus).25
An essential event for the activity of daptomy-
cin is calcium-mediated interaction with the cell 
membrane, a property that this antibiotic shares 
with related cationic antimicrobial peptides that 
are part of the human host defense against mi-
crobes. The change in the bacterial surface also 
appears to play an important role in the interac-
tion of daptomycin with the cell membrane, and 
it has been postulated that a more positively 
charged cell envelope “repels” the cationic dap-
tomycin from the cell membrane, contributing to 
the development of resistance.15 A major factor in 
the cell-envelope charge is the phospholipid com-
position of the inner and outer cell-membrane 
leaflets, such as the negatively charged phospho-
lipid cardiolipin and the positively charged amino 
derivatives of phosphatidylglycerol. In some S. au-
reus isolates, reduced susceptibility to daptomycin 
has been attributed to a decrease in the negative 
surface charge of the cell membrane as a result 
of modifications in phospholipid content, main-
ly through increased synthesis and translocation 
(“flipping”) of the positively charged lysyl-phos-
phatidylglycerol from the inner to the outer leaf-
let of the cell membrane.15,26 It has also been 
shown that lysyl-phosphatidylglycerol attenuates 
membrane perturbations caused by cationic an-
timicrobial peptides.27
Table 2. Amino Acid Changes in Daptomycin-Susceptible and Daptomycin-Resistant Clinical and Laboratory-Derived 
Isolates of Vancomycin-Resistant Enterococcus faecalis.*
Isolate
MIC of  
Daptomycin† Predicted Amino Acid Change
Cls LiaF GpdD
μg/ml
S613‡  1 None None None
R712‡ 12 Deletion of Lys  
at position 61
Deletion of Ile  
at position 177
Deletion of Ile  
at position 170
S613R§ 12 None Deletion of Ile  
at position 177















¶ 12 None Deletion of Ile  
at position 177
Deletion of Ile  
at position 170
* Cls denotes cardiolipin synthetase, GdpD glycerophosphoryl diester phosphodiesterase, and LiaF lipid II cycle-interfering-
antibiotics protein.
† The minimal inhibitory concentration (MIC) of daptomycin was determined with the use of Etest (AB Biodisk)11 on brain–
heart infusion agar.
‡ The clinical strain pair of E. faecalis isolates (S613 and R712) was recovered from a single patient, with S613 recovered 
before the administration of daptomycin and R712 recovered after the administration of daptomycin.4
§ S613R is an in vitro derivative of E. faecalis S613 that was obtained by serial passage through increasing concentrations 
of daptomycin.
¶ In this isolate, the native allele of S613 was replaced with the allele belonging to the R712 isolate.
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Our findings in this study indicate that the 
development of resistance to daptomycin in the 
vancomycin-resistant E. faecalis isolate R712, like 
the development of resistance in S. aureus, is as-
sociated with alterations in the cell envelope and 
biophysical properties of the cell membrane. How-
ever, the genes linked to these changes in entero-
cocci appear to be different from those described 
in S. aureus. Indeed, in the R712 isolate, none of 
the genes associated with the emergence of re-
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Figure 1. Transmission Electron Microscopy of the Cell Envelope of Enterococcus faecalis Isolates, One Susceptible to Daptomycin (S613) 
and the Other Resistant (R712).
At high magnification, cells in the S613 isolate have symmetric septa, with only a single septum observed between two cells, and cell 
separation is easily detected, with single cells visible (Panels A, B, and G). In contrast, multiple septal structures can be seen before 
complete cell separation in the R712 isolate (Panels A and B, red arrowheads). There are also prominent distortions in the cell envelopes 
of R712 cells. First, the envelopes appear to be altered at the point of cell contact (which is likely to be the point at which the cells sepa-
rate) (Panels B, D, and E; blue arrowheads), and the surfaces of the R712 cells lack the smooth appearance of the S613 cells, even when 
they are in close proximity (a feature observed in all R712 cells analyzed) (Panel E). Second, several structures appear to be connecting 
the R712 cells (Panels B, C, and F; purple arrowheads); these connecting projections, which were not observed in S613 cells, appear to 
originate in the cell envelope and maintain the contact between adjacent cells even after the cells have separated. Third, localized pro-
trusions of the cell envelope are a common feature of R712 cells (Panels G and H, black arrowheads). These protrusions were usually ob-
served in proximity to a septal stricture that appeared to originate from the cell envelope. On the other hand, the surface of S613 cells is 
smooth and symmetric, without any obvious projections or protrusions (more than 100 cells analyzed) (Panels G and H).
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sistance to daptomycin in S. aureus20-24 differed 
from those in the daptomycin-susceptible paren-
tal isolate, S613. Instead, our data provide direct 
evidence that changes in two genes — namely, 
liaF and gdpD — are sufficient for the develop-
ment of resistance to daptomycin in the E. faeca-
lis clinical strain pair.
The alteration of the LiaFSR system is probably 
a pivotal initial event in the development of re-
sistance, since replacement of only the liaF allele 
in the S613 isolate with that from the R712 iso-
late decreased the susceptibility of the S613 iso-
late to daptomycin.
LiaF is part of the three-component LiaFSR 
regulatory system, which is known to orchestrate 
the response of the cell envelope to antibiotics and 
antimicrobial peptides in some gram-positive bac-
teria. The LiaFSR system has been well character-
ized in B. subtilis,8,16 Streptococcus mutans,17 and 
pneumococci.18 In B. subtilis and S. mutans, the 
LiaFSR system is usually activated by the presence 
of antibiotics that disrupt cell-membrane and 
peptidoglycan synthesis through alterations of 
lipid-II metabolism (i.e., bacitracin, daptomycin, 
ramoplanin, nisin, and vancomycin).16,19 In B. sub-
tilis, LiaF is a membrane-anchored, negative regu-
lator of LiaS (which is the sensor protein of the 
system and also functions as a histidine kinase 
that phosphorylates the cognate-response regu-
lator, LiaR).8 Therefore, it is predicted that mu-
tations in liaF may release the inhibitory effect of 
LiaS, resulting in activation of this system.
Nonetheless, our genetic experiments indicat-
ed that mutations in liaF are not sufficient for full 
expression of the resistant phenotype. Indeed, the 
subsequent introduction of a mutation in gdpD 
was sufficient to increase the MIC to a level similar 
to that in the daptomycin-resistant R712 isolate, 
indicating that both genes are needed for the full 
expression of the resistant phenotype. Thus, it 
appears that resistance to daptomycin in entero-
cocci requires two major steps. First, an initial 
activation of the LiaFSR system occurs through 
mutations in liaF or other components of the 
LiaFSR system (which might be selected by means 
of exposure to antibiotics that alter lipid-II metabo-
lism); activation of the system may influence cell-
envelope homeostasis by affecting the transcrip-
Table 3. Changes in Genes Encoding Cls or Members of the LiaFSR System in Clinical Isolates of Enterococci.*
Isolate MIC† Predicted Amino Acid Change
Daptomycin Vancomycin Cls LiaFSR‡
μg/ml
Enterococcus faecalis
R508  6   2 None Ala180→Thr of LiaS
E. faecium
S447§  2 256 None None
R446§ 32  16 Arg218→Gln None
R501 48 256 Arg218→Gln None
R494 64   1 None Leu39→Phe of LiaF
Trp73→Cys of LiaR
R496 32   1 Asn13→Ile Ile144→Thr of LiaF
R497 24   1 Insertion of Met-Pro-Leu  
at position 110
Thr120→Ala of LiaS
R499 48 256 His215→Arg Trp73→Cys of LiaR
* Cls denotes cardiolipin synthetase. LiaFSR is a lipid II cycle-interfering-antibiotics system.
† The minimal inhibitory concentration (MIC) of daptomycin was determined with the use of Etest (AB Biodisk)11 on 
brain–heart infusion agar, and the MIC of vancomycin with the use of the agar dilution method.25
‡ LiaFSR proteins are homologous to YvqF, VraS, and VraR, which were previously described in Staphylococcus aureus.
§ The clinical strain pair of E. faecium (S447 and R446) was recovered from a single patient, with S447 recovered before 
the administration of daptomycin and R446 recovered after the administration of daptomycin.5
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tion of several genes that can help mitigate the 
damage caused by the antibiotic. Second, a sub-
sequent alteration in the cell membrane occurs 
through changes in enzymes involved in phospho-
lipid metabolism (e.g., GdpD or Cls), leading to 
critical and compensatory changes in the com-
position or distribution of phospholipids in the cell 
membrane. Indeed, the bacterial GdpD has been 
shown to be important in glycerol metabolism, 
hydrolyzing several cell-membrane glycerophos-
phodiesters28 that affect phospholipid metabo-
lism. Similarly, cardiolipin has been found to play 
several key roles in cell-membrane physiology, 
such as in bacterial cell division,29,30 transporter 
localization (in Escherichia coli),31 and the trigger-
ing of compensatory changes in the phospholipid 
composition of the cell membrane, which affect 
bacterial adaptive responses.32
In support of our hypothesis that the changes 
discussed above are also important in other dap-
tomycin-resistant isolates of enterococci, we found 
changes in genes encoding the LiaFSR system and 
Cls in three additional clinical isolates of dapto-
mycin-resistant enterococci. In four other dapto-
mycin-resistant clinical isolates, only one of these 
genes appeared to be altered, suggesting that ad-
ditional loci involved in cell-wall homeostasis or 
phospholipid metabolism may be important in 
these enterococcal isolates. Indeed, unlike the 
S. aureus cell membrane, the enterococcal cell 
membrane has several amino acid–containing 
phospholipids, apart from lysyl-phosphatidylglyc-
erol (including arginyl-phosphatidylglycerol and 
alanyl-phosphatidylglycerol33). In addition, there 
are other two-component systems present in en-
terococci that can potentially modulate the re-
sponse to the antimicrobial challenge.
It is also of interest that the amino acid chang-
es in the LiaF and GdpD proteins of the R712 
isolate occurred in a region that harbors repeats 
of Ile; this suggests that these in-frame changes 
may have originated from recombination between 
adjacent repetitive nucleotide sequences. Mutations 
that occur by means of this mechanism were ob-
served to alter the function of LiaF in B. subtilis8 
and the histidine kinase VanSB involved in E. fae-
cium resistance to vancomycin,34 and these muta-
tions suggest the presence of an underlying ge-
netic mechanism for the development of resistance 
to daptomycin in E. faecalis.
In summary, our data indicate that the emer-
gence of resistance to daptomycin is the result of 
concomitant alterations in genes (liaF and gdpD) 
encoding proteins that are probably involved in 
regulating the stress response to antimicrobial 
agents acting on the cell envelope and enzymes 
that are responsible for phospholipid metabolism 
in the cell membrane.
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